HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.

AbstractBACKGROUND:
Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that usually occurs in infants. It is commonly associated with Kasabach-Merritt phenomenon which is directly responsible for the significant morbidity and mortality, including hemodynamic instability, local invasion, and compression of vital structures. Treatment is particularly difficult for those who had no response to conventional therapies. This paper wants to share experience of mTOR inhibitors sirolimus in the treatment of refractory KHE.
MATERIALS AND METHODS:
Six cases of refractory KHE were diagnosed and treated in Children's Hospital of Fudan University from Jan 2010-June 2013; all of them were treated with sirolimus in June 2012 after failing multiple other therapies.
RESULTS:
In six patients, gender was equally distributed between male and female patients. The mean age at the time of initial diagnosed as KHE was 3.1 ± 1.8 months. All of them had been pretreated with at least 2 medical therapies. All of them showed significant improvement in clinical status with tolerable side effects. The average time to response was 5.3 ± 1.0 days; the average stabilization time of platelet was 15.1 ± 8.0 days; and the average time for sirolimus treated as single agent was 1.7 ± 0.4 months. No recurrence of their symptoms happened.
CONCLUSIONS:
Sirolimus appears to be effective and safe in patients with life-threatening KHE and represents a promising tool in treating refractory KHE.
AuthorsLi Kai, Zuopeng Wang, Wei Yao, Kuiran Dong, Xianmin Xiao
JournalJournal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 140 Issue 3 Pg. 471-6 (Mar 2014) ISSN: 1432-1335 [Electronic] Germany
PMID24464150 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Sirolimus
Topics
  • Antibiotics, Antineoplastic (administration & dosage, therapeutic use)
  • Drug Administration Schedule
  • Female
  • Hemangioendothelioma (drug therapy)
  • Humans
  • Infant
  • Infant, Newborn
  • Kasabach-Merritt Syndrome (drug therapy)
  • Male
  • Retrospective Studies
  • Sarcoma, Kaposi (drug therapy)
  • Sirolimus (administration & dosage, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: